Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

Inclusion Criteria

• •Have a medically documented diagnosis of hemophilia A or B that is being treated prophylactically with a factor replacement product not designed to have a prolonged half-life and satisfy a therapeutic indication for rFVIIIFc/rFIXFc per the approved local label
• •Have at least 50 prior exposure days (EDs) to any combination of factor replacement products
• •Have documented pre-study data available that confirm fulfillment of the eligibility criteria
• •Have no measurable inhibitor activity in a sample obtained within 4 weeks prior to the Baseline visit, and absence of clinical signs or symptoms of decreased response to the current factor replacement product